点击上方蓝字关注中泰国际中流砥柱泰山可倚中泰国际助力减重疗法概念股-“派格生物医药”(2565.HK)成功上市!中泰国际作为联席账簿管理人及联席牵头经办人的项目,减重疗法概念股 –派格生物医药( 杭州) 股份有限公司(“派格生物医药”, 证券代码:2565.HK)于2025年5月27日成功上市。派格生物医药本次全球发行约1928.35万股H股,定价为每股H股15.60港元,集资总额约3.01亿港元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.